# A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa

> **NCT00119613** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 600 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** placebo
- **DRUG:** darbepoetin alfa

## Key facts

- **NCT ID:** NCT00119613
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2007-01
- **Final completion:** 2007-04
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2008-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00119613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00119613, "A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00119613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*